published Thursday
found that among patients who were prescribed GLP-1 medications for diabetes, those who had higher copay costs were less likely to still be on the medication after a year compared to those with a lower copays. The study analyzed information from more than 90,000 adults prescribed GLP-1 drugs or or another new type of medication for their diabetes, to see who consistently took the medications. It found that those who had to pay $50 or more each month were 50% less likely to keep taking the medications compared to those who paid less than $10.
The researchers looked at information between 2014 and 2020, a time before GLP-1 medications were approved for weight loss. As interest in the medications grows, whether or not Americans can afford them could determine how effective they are. Especially after a
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
A castle in Scotland is up for sale for $37,000 – but beware a bargainInsider tells the global tech, finance, markets, media, healthcare, and strategy stories you want to know.
Source: BusinessInsider - 🏆 729. / 51 Read more »